HOME > News > 2014

RIBOMIC, Inc. is a leading company in the world developing innovative aptamer therapeutics.

2014

 December 1, 2014 The joint research work originated in the CREST (JST) program (2005-2010) on the multi-target development of RNA-based ‘nanosensors’ and ‘modulators’ was presented at the 2014 Annual Conference of Molecular Biology Society of Japan (Yokohama, November 25-27). The title of the presentation was“NMR analysis of the interaction of AML and RNA”and the contributing institutions were RIBOMIC Inc., The University of Tokyo, Chiba Institute of Technology and Saitama Cancer Center
 November 27, 2014 The collaborative work between The University of Tokyo Institute of Medical Science (PI: the former professor Yoshikazu Nakamura) and Zenyaku Kogyo Co., Ltd. developed under the Technical Advisor Agreement of RIBOMIC Inc. and Zenyaku was presented at the 2014 Annual Conference of Molecular Biology Society of Japan (Yokohama, November 25-27). The title of presentation was“Anti-Interleukin-17 Aptamer Inhibits Interleukin-23-Induced Psoriasis-like Dermatitis in C57BL/6J Mice”.
 November 27, 2014 The collaborative work between The University of Tokyo Institute of Medical Science (PI: the former professor Yoshikazu Nakamura) and Zenyaku Kogyo Co., Ltd. developed under the Technical Advisor Agreement of RIBOMIC Inc. and Zenyaku was presented at the 2014 Annual Conference of American College of Rheumatology (Boston, November 14 -19). The title of presentation was“Improvement of the Stability of RNA Aptamers against Interleukin-17A”.
 November 18, 2014 The collaborative work between National Institute of Health Science and RIBOMIC Inc. was presented at the 2014 annual conference of Japanese Society for Biomaterials (Tokyo, November 17-18). The title of presentation was“Development of Novel Medical Biomaterials Using RNA Aptamer”, at Japanese Society of Japanese Society for Biomaterials. (Tokyo, Japan17-18 November 2014)
 November 10, 2014 Yoshikazu Nakamura, President and CEO, will speak at the 17th A-IMBN Annual Conference in Manila (December 1-2, 2014) on “Aptamer Therapeutics Targeting Lung Fibrosis”.
 September 25, 2014 The material patent of RMB004 on “Anti- NGF Aptamer and Its Usage” was granted in Japan.
 August 20, 2014 We received approval to list our shares on the Tokyo Stock Exchange Mothers Market.
 July 31, 2014 We received the notice of allowance for the material patent of RMB004 on “Anti NGF Aptamer and Its Usage” in Japan.
The material patent of RMB007 on “Anti- FGF2 Aptamer and Its Usage” was granted in the USA.
 April 30, 2014 We entered into the worldwide exclusive license agreement for the anti-NGF aptamer (RBM004) with Fujimoto Pharmaceutical Corporation.
 April 17, 2014 We entered into the collaborative research contract with Taisho Pharmaceutical Co., Ltd. for the therapeutic aptamer discovery program (appeared in the newspaper of Nikkei at page 14).